Assessing Safety of Fibroblast Cell Therapy in Multiple Sclerosis: Hamid Khoja, PhD
The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology in MS.
“What we’ve seen in our limited clinical trial is that these tolerogenic fibroblasts, or CybroCell, we don’t see any side effects, or we haven’t seen any side effects.”
This content originally appeared on our sister site, NeurologyLive.
Fibroblast cell technology seems to be safe for use in patients with multiple sclerosis (MS) and may offer a unique treatment approach. Hamid Khoja, PhD, chief scientific officer, FibroBiologics, discussed the technology, dubbed CYMS101, and the limited clinical trial that evaluated its safety.
Kohja discussed how patients treated with a 1-time infusion of CYMS101 did not experience any adverse events (AEs), unlike those treated with humanized monoclonal antibodies, although he did note the small scale of the study,
Patients enrolled in the safety study were monitored post-infusion for 4 hours and then at 4-week intervals for complete blood count and blood chemistry, where investigators again did not notice a difference. While experts opted for a single dose in the initial study, in the phase 1/2 clinical trial, multiple doses will be assessed, and investigators will look at multiple concentrations of cells to determine efficacy and safety. According to Khoja, FibroBiologics is aiming for a staggered approach to the clinical trial and anticipates filing an investigational new drug application in the third quarter of 2022.
Urgency of Funding and Equity in Neuromuscular Research and Care
March 31st 2025Robert Califf, MD, MACC, a cardiologist and former FDA commissioner, discussed the necessity of policy and funding efforts for neuromuscular disorders, the stress on the clinical care system, and the need to acknowledge healthcare inequities.
